Antiviral Drugs Specific for Coronaviruses in Preclinical Development

Overview

Journal Curr Opin Virol

Publisher Elsevier

Specialty Microbiology

Date 2014 Jul 6

PMID 24997250

Citations 55

Authors

Adeyemi O Adedeji

Stefan G Sarafianos

Affiliations

Soon will be listed here.

Abstract

Coronaviruses are positive stranded RNA viruses that cause respiratory, enteric and central nervous system diseases in many species, including humans. Until recently, the relatively low burden of disease in humans caused by few of these viruses impeded the development of coronavirus specific therapeutics. However, the emergence of severe acute respiratory syndrome coronavirus (SARS-CoV), and more recently, Middle East respiratory syndrome coronavirus (MERS-CoV), has impelled the development of such drugs. This review focuses on some newly identified SARS-CoV inhibitors, with known mechanisms of action and their potential to inhibit the novel MERS-CoV. The clinical development of optimized versions of such compounds could be beneficial for the treatment and control of SARS-CoV, the current MERS-CoV and other future SARS-like epidemics.

Citing Articles

Ayurvedic and Chinese Herbs against Coronaviruses.

Gasmi A, Kanwal S, Oliinyk P, Lysiuk R, Shanaida M, Benahmed A Curr Pharm Des. 2024; 30(21):1681-1698.

PMID: 38685809 DOI: 10.2174/0113816128269864231112094917.

Free energy perturbation-based large-scale virtual screening for effective drug discovery against COVID-19.

Li Z, Wu C, Li Y, Liu R, Lu K, Wang R Int J High Perform Comput Appl. 2024; 37(1):45-57.

PMID: 38603271 PMC: 9396747. DOI: 10.1177/10943420221117797.

Development of Fluorescence-Based Assays for Key Viral Proteins in the SARS-CoV-2 Infection Process and Lifecycle.

Deng M, Zhang C, Yan W, Chen L, He B, Li Y Int J Mol Sci. 2024; 25(5).

PMID: 38474097 PMC: 10932265. DOI: 10.3390/ijms25052850.

Discovery of Novel Cysteine Protease Inhibitors for the Treatment of Coronavirus (COVID-19).

K DE S Curr Med Chem. 2023; 31(9):1165-1169.

PMID: 37211851 PMC: 10788913. DOI: 10.2174/0929867330666230519163305.

In Silico Approach for the Evaluation of the Potential Antiviral Activity of Extra Virgin Olive Oil (EVOO) Bioactive Constituents Oleuropein and Oleocanthal on Spike Therapeutic Drug Target of SARS-CoV-2.

Geromichalou E, Geromichalos G Molecules. 2022; 27(21).

PMID: 36364398 PMC: 9655607. DOI: 10.3390/molecules27217572.

References

Shie J, Fang J, Kuo C, Kuo T, Liang P, Huang H . Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease. J Med Chem. 2005; 48(13):4469-73. DOI: 10.1021/jm050184y. View

Rota P, Oberste M, Monroe S, Nix W, Campagnoli R, Icenogle J . Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science. 2003; 300(5624):1394-9. DOI: 10.1126/science.1085952. View

Lieberman-Blum S, Fung H, Bandres J . Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection. Clin Ther. 2008; 30(7):1228-50. DOI: 10.1016/s0149-2918(08)80048-3. View

Loutfy M, Blatt L, Siminovitch K, Ward S, Wolff B, Lho H . Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA. 2003; 290(24):3222-8. DOI: 10.1001/jama.290.24.3222. View

Yang Z, Huang Y, Ganesh L, Leung K, Kong W, Schwartz O . pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J Virol. 2004; 78(11):5642-50. PMC: 415834. DOI: 10.1128/JVI.78.11.5642-5650.2004. View

Eda Y, Murakami T, Ami Y, Nakasone T, Takizawa M, Someya K . Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection. J Virol. 2006; 80(11):5563-70. PMC: 1472178. DOI: 10.1128/JVI.02095-05. View

Adedeji A, Severson W, Jonsson C, Singh K, Weiss S, Sarafianos S . Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms. J Virol. 2013; 87(14):8017-28. PMC: 3700180. DOI: 10.1128/JVI.00998-13. View

Booth C, Matukas L, Tomlinson G, Rachlis A, Rose D, Dwosh H . Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003; 289(21):2801-9. DOI: 10.1001/jama.289.21.JOC30885. View

Adedeji A, Singh K, Calcaterra N, DeDiego M, Enjuanes L, Weiss S . Severe acute respiratory syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicase. Antimicrob Agents Chemother. 2012; 56(9):4718-28. PMC: 3421890. DOI: 10.1128/AAC.00957-12. View

10.

Lee C, Kuo C, Hsu M, Liang P, Fang J, Shie J . Structural basis of mercury- and zinc-conjugated complexes as SARS-CoV 3C-like protease inhibitors. FEBS Lett. 2007; 581(28):5454-8. PMC: 7094272. DOI: 10.1016/j.febslet.2007.10.048. View

11.

Tanner J, Zheng B, Zhou J, Watt R, Jiang J, Wong K . The adamantane-derived bananins are potent inhibitors of the helicase activities and replication of SARS coronavirus. Chem Biol. 2005; 12(3):303-11. PMC: 7110988. DOI: 10.1016/j.chembiol.2005.01.006. View

12.

Lu I, Huang C, Peng Y, Lin Y, Hsieh H, Chen C . Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities. J Med Chem. 2006; 49(9):2703-12. DOI: 10.1021/jm051129s. View

13.

Liang P . Characterization and inhibition of SARS-coronavirus main protease. Curr Top Med Chem. 2006; 6(4):361-76. DOI: 10.2174/156802606776287090. View

14.

Dau B, Holodniy M . Novel targets for antiretroviral therapy: clinical progress to date. Drugs. 2009; 69(1):31-50. DOI: 10.2165/00003495-200969010-00003. View

15.

Sung J, Wu A, Joynt G, Yuen K, Lee N, Chan P . Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. Thorax. 2004; 59(5):414-20. PMC: 1746995. DOI: 10.1136/thx.2003.014076. View

16.

Miller M, Hazuda D . HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications. Drug Resist Updat. 2004; 7(2):89-95. DOI: 10.1016/j.drup.2004.03.003. View

17.

Tripet B, Howard M, Jobling M, Holmes R, Holmes K, Hodges R . Structural characterization of the SARS-coronavirus spike S fusion protein core. J Biol Chem. 2004; 279(20):20836-49. PMC: 8060857. DOI: 10.1074/jbc.M400759200. View

18.

Haagmans B, Al Dhahiry S, Reusken C, Raj V, Galiano M, Myers R . Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation. Lancet Infect Dis. 2013; 14(2):140-5. PMC: 7106553. DOI: 10.1016/S1473-3099(13)70690-X. View

19.

Danilczyk U, Penninger J . Angiotensin-converting enzyme II in the heart and the kidney. Circ Res. 2006; 98(4):463-71. DOI: 10.1161/01.RES.0000205761.22353.5f. View

20.

Shao Y, Yang W, Peng H, Hsu M, Tsai K, Kuo T . Structure-based design and synthesis of highly potent SARS-CoV 3CL protease inhibitors. Chembiochem. 2007; 8(14):1654-7. PMC: 7162026. DOI: 10.1002/cbic.200700254. View